logo.jpg
Fenix Marine Services Demonstrates Its Commitment To Corporate Social Responsibility
April 28, 2021 16:24 ET | Fenix Marine Services
LOS ANGELES, April 28, 2021 (GLOBE NEWSWIRE) -- Fenix Marine Services released its Corporate Social Responsibility Annual Report 2020 which documents Fenix’s accomplishments over the past year....
logo.jpg
Fenix Marine Services Achieves Carbon Neutral Electricity Through Renewable Energy Credits
January 25, 2021 10:48 ET | Fenix Marine Services
LOS ANGELES, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Fenix Marine Services LTD (“Fenix” or “FMS”), one of the largest terminal facilities at the Port of Los Angeles, today announced that it has used...
TrackX.png
TrackX and Topl Announce Strategic Partnership Combining Blockchain with Asset Management to Empower End-to-End Supply Chain Transparency
December 03, 2020 08:00 ET | TrackX Holdings Inc.
Global IOT-enabled asset management and supply chain solutions company partners with ESG technology startup to deliver supply chain transparencyIntegrated solution will combine Topl’s purpose-built...
Equillium_Square_Logo.png
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
October 29, 2020 16:13 ET | Equillium
Equillium plans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020 FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Equillium,...
logo.jpg
Fenix Marine Services Re-Affirms its Commitment to Corporate Social Responsibility
October 28, 2020 19:42 ET | Fenix Marine Services
LOS ANGELES, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Fenix Marine Services (“FMS”), one of the largest container terminals in San Pedro Bay, has published today its Corporate Social Responsibility (CSR)...
Equillium_Square_Logo.png
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
September 15, 2020 08:07 ET | Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....
lyra logo.jpg
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
September 10, 2020 18:00 ET | Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
lyra logo.jpg
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
September 03, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
lyra logo.jpg
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET | Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
lyra logo.jpg
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 04, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...